Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole in Moderate to Severe Idiopathic RLS
NCT00275457Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2002
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing Pramipexole with Placebo (2 arms). Primary endpoints: International Restless Legs Syndrome Study Group Rating Scale Total Score at 6 weeks and Clinical Global Impressions - Improvement Responders at 6 weeks. Started Oct 2002; status: completed.
02
Drugs
pramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00275457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275457.